β-Secretase Inhibitor IV (β-分泌酶抑制剂IV)是一种细胞可渗透的有效抑制剂,与BACE-1活性位点结合并阻断其蛋白水解活性(BACE-1,人的IC50 = 15 nM,在HEK293-APPNFEV细胞中sAPP_NF的IC50=29 nM)。显示出比其他天冬氨酰蛋白酶更高的选择性(BACE-2、组织蛋白酶D和肾素的IC50...
英文名称:beta-Secretase Inhibitor IV CAS:797035-11-1 纯度:98% HPLC LCMS 包装信息:100MG;1G;5G 备注:量大优惠,现货促销 深圳聚合生化科技有限公司 联系电话: +86-400-002-6226 +86-13028896684 产品介绍: 英文名称:BACE-1 inhibitor CAS:797035-11-1 ...
相关产品:Elenbecestat | BACE1-IN-1 | LY2886721 | AZD3839 free base | Eslicarbazepine | 艾司利卡西平 | Se-Methylselenocysteine | L-硒甲基硒代半胱氨酸 | β-Secretase Inhibitor IV | hAChE/hBACE-1-IN-3 | Verubecestat | 维罗司他 | BACE2-IN-1 热销产品:Rasagiline | Afatinib (dimaleate) |...
6.2 Multi target BACE-1 inhibitor Fernández-Bachiller et al. designed and synthesized a class of dual inhibitors of AChE and BACE-1. They introduced tacrine-6-OH-4-oxo-4H-chromene hybrid, compound 60, described as a potent dual binding site ChEs (AChE IC50 = 75 nM, BuChE IC50 ...
β-Secretase Inhibitor IV (β-分泌酶抑制剂IV)是一种细胞可渗透的有效抑制剂,与BACE-1活性位点结合并阻断其蛋白水解活性(BACE-1,人的IC50 = 15 nM,在HEK293-APPNFEV细胞中sAPP_NF的IC50=29 nM)。显示出比其他天冬氨酰蛋白酶更高的选择性(BACE-2、组织蛋白酶D和肾素的IC50...
In order to further validate the use of Substrate IV for inhibition studies, the inhibitory potency of the well-known BACE1 peptide InhibitorIV (IC50: 0.19卤0.02渭M) and of the natural compound Uleine (IC50: 0.57卤0.05) were determined in the optimized on-line hrBACE1-IMER. The IC50 ...
Abad-Zapatero, C. et al. (1996). “Structure of a Secreted Aspartic Protease From C. Albicans Complexed with a Potent Inhibitor: Implications for the Design of Antifungal Agents,” Protein Science 5:640-652. Abbenate, G. et al. (Feb. 5, 2000). “Inhibitors of β-Amyloid Formation Ba...
In order to further validate the use of Substrate IV for inhibition studies, the inhibitory potency of a well-known beta-secretase peptide inhibitor was determined. A further application with uleine as BACE1 inhibitor was carried out to prove the system suitability for natural compounds. 展开 ...
R. et al., “Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer's disease,” Neurology 66:602-604 (2006). Siemers, E. R. et al., “Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-β After Inhibition of γ-Secretase,” ...
The present invention provides a method for the treatment of neuronal disorders, in a mammal such as human, which method comprises administering an effective, non-toxic and pharmaceutiacally acceptable amount of at least one QC inhibitor, optionally in combination with at least one agent, ...